Previous 10 | Next 10 |
2024-06-23 06:52:10 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.2% to $126.57 on volume of 604,432,871 shares American Rebel Holdings Inc. (AREB) rose 152.5% to $0.76 on volume of 367,740,589 shares Sirius XM Holdings Inc. (SIRI) rose 1.0% to $2.93 on volume of 329...
2024-06-21 15:00:42 ET More on the markets SPY: The Upside Is Likely Capped SPY: Rating Downgrade Due To Overvaluation Perfect Time For November Election Protection UBS says the current market conditions and the late 1990s have many differences Wolfe ...
2024-06-21 09:15:03 ET Evercore ISI analyst issues OUTPERFORM recommendation for INSM on June 21, 2024 08:10AM ET. The previous analyst recommendation was Outperform. INSM was trading at $64.71 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Shares of Insmed Incorporated (NASDAQ: INSM) traded at a new 52-week high today and are currently trading at $63.92. So far today, approximately 661.25k shares have been exchanged, as compared to an average 30-day volume of 5.3M shares. Insmed Incorporated, a biopharmaceutical company, develo...
2024-06-12 14:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-05 09:00:13 ET Stephen Willey from Stifel Nicolaus issued a price target of $74.00 for INSM on 2024-06-05 07:25:00. The adjusted price target was set to $74.00. At the time of the announcement, INSM was trading at $57. The overall price target consensus is at $59...
Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire BRIDGEWATER, N.J. , June 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with...
Insmed to Host Commercial Webinar on June 4, 2024 PR Newswire BRIDGEWATER, N.J. , May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare disease...
2024-05-30 14:50:45 ET More on Insmed Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade) Insmed, Inc. (INSM) Q1 2024 Earnings Call Transcript Insmed intends to raise $500M via equity offering Insmed surges on late-stage win for lung disease ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 08:00:06 ET Vamil Divan from Guggenheim issued a price target of $95.00 for INSM on 2024-07-09 06:44:00. The adjusted price target was set to $95.00. At the time of the announcement, INSM was trading at $70.05. The overall price target consensus is at $72.91 w...
Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference PR Newswire —New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Bren...